ANI Pharmaceuticals reported positive Phase 4 trial results for ILUVIEN (fluocinolone acetonide intravitreal implant) in treating chronic non-infectious uveitis affecting the posterior segment. The trial met both co-primary endpoints with statistically significant improvements in visual acuity (+3.6 letters) and central subfield thickness reduction (-157.5 microns) at 6 months. Safety profile was consistent with prior trials, with ocular hypertension (6%) and cataract (5%) as the most common adverse events.

ANI Pharmaceuticals CFO Stephen Carey sold 3,313 shares worth $285,000 on July 2, 2026, through a pre-established Rule 10b5-1 trading plan adopted in March. The sale represented only 2% of his direct holdings, leaving him with approximately $15.3 million in company stock. The transaction involved exercising options at $49.51 and selling at $86.00 per share. Despite the stock's 32% one-year return, the article characterizes this as routine portfolio management, noting the company's strong fundamentals including 20.5% Q1 revenue growth and raised full-year guidance.

Global Alpha Capital Management sold 228,895 shares of Ani Pharmaceuticals (ANIP) in Q1 2026, worth approximately $17.87 million, reducing its position by about 39%. The sale reduced ANIP from Global Alpha's ninth-largest holding to outside the fund's top five positions. Despite strong Q1 earnings with 20.5% sales growth and raised 2026 guidance, the stock has underperformed the S&P 500 significantly.

An ANI Pharmaceuticals executive sold 4,772 shares worth $357,471 on March 11, 2026, representing routine portfolio trimming rather than a bearish signal. The company reported record 2025 revenue of $883.4 million (up 43.8% YoY) driven by strong rare disease segment growth, with management guiding for over $1 billion in 2026 revenue.

ANI Pharmaceuticals announced it will release its fourth quarter and full year 2025 financial results on February 27, 2026, prior to market open. The company expects full year 2025 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above guidance ranges. A conference call will be hosted by CEO Nikhil Lalwani and other executives to discuss the results.

Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather than a loss of confidence. ANI's future returns will depend on sustained rare disease growth and margin discipline rather than multiple expansion.

CG Oncology announced that its leadership will participate in two upcoming investor conferences in September 2025, presenting at the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference.

Cg Oncology reported a wider net loss in Q2 2025, with no revenue and increased R&D expenses. The company continues developing a gene therapy for bladder cancer and plans to submit a Biologics License Application in Q4 2025.

ANI Pharmaceuticals reported record quarterly net revenues of $197.1 million, a 43.4% year-over-year growth. The company's Rare Disease business generated $69.0 million in quarterly net revenues and presented preclinical data on the use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis mouse model.

ANI Pharmaceuticals reported strong Q4 results, with adjusted EPS and sales beating estimates. The company raised its 2025 guidance for revenue and adjusted EPS, driven by growth in its Cortrophin Gel, generics, and branded products.

ANI Pharmaceuticals, Inc. announced that it will release its third quarter 2024 financial results on November 8, 2024, and host a conference call to discuss the results.

Avadel Pharmaceuticals received FDA approval to expand the label of its narcolepsy drug Lumryz to include treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older. This expands the drug's indication to the pediatric population and is expected to boost sales.